Scientific Advisory Board
The Scientific Advisory Board (SAB) comprises experts in oncology, immunology, protein engineering, drug discovery and development.The SAB provides strategic and scientific counsel to IGI’s management and research & development team to help advance the company’s proprietary BEAT® platform and multispecifics directed at blood cancers and solid tumors.
Adam Cohen, M.D.
Associate Professor of Medicine, Director, Myeloma Immunotherapy, at the University of Pennsylvania, USA
Dr. Cohen is a graduate of Harvard University. He received his medical degree and residency training from University of Pennsylvania, and completed his hematology/medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Dr. Cohen has lectured frequently and has been widely published in journals and book chapters on the areas of cancer immunotherapy and multiple myeloma.
Adam Cohen, M.D.
Associate Professor of Medicine, Director, Myeloma Immunotherapy, at the University of Pennsylvania, USA
Dr. Cohen is a graduate of Harvard University. He received his medical degree and residency training from University of Pennsylvania, and completed his hematology/medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Dr. Cohen has lectured frequently and has been widely published in journals and book chapters on the areas of cancer immunotherapy and multiple myeloma.
Adam Cohen, M.D.
Associate Professor of Medicine, Director, Myeloma Immunotherapy, at the University of Pennsylvania, USA
Dr. Cohen is a graduate of Harvard University. He received his medical degree and residency training from University of Pennsylvania, and completed his hematology/medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Dr. Cohen has lectured frequently and has been widely published in journals and book chapters on the areas of cancer immunotherapy and multiple myeloma.
Wolf Hervé Fridman, M.D., Ph.D.
Professor Emeritus of Immunology, at Université Paris Cité Medical School, France
Dr. Fridman’s focus is on the role the immune system plays in the control of human malignancies and he is world-renowned in the area of tumor immunology.
Wolf Hervé Fridman, M.D., Ph.D.
Professor Emeritus of Immunology, at Université Paris Cité Medical School, France
Dr. Fridman’s focus is on the role the immune system plays in the control of human malignancies and he is world-renowned in the area of tumor immunology.
Wolf Hervé Fridman, M.D., Ph.D.
Professor Emeritus of Immunology, at Université Paris Cité Medical School, France
Dr. Fridman’s focus is on the role the immune system plays in the control of human malignancies and he is world-renowned in the area of tumor immunology.
Sergio Giralt, M.D.
Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, USA
Dr. Giralt’s clinical research focus is on stem cell transplantation for patients with blood disorders. He trained and worked at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, Dr. Giralt joined the faculty of Memorial Sloan-Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Sergio Giralt, M.D.
Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, USA
Dr. Giralt’s clinical research focus is on stem cell transplantation for patients with blood disorders. He trained and worked at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, Dr. Giralt joined the faculty of Memorial Sloan-Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Sergio Giralt, M.D.
Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, USA
Dr. Giralt’s clinical research focus is on stem cell transplantation for patients with blood disorders. He trained and worked at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, Dr. Giralt joined the faculty of Memorial Sloan-Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Philippe Moreau, M.D., Ph.D.
Professor of Clinical Hematology at the University Hospital of Nantes at the Medical University of Nantes in France
Professor Moreau is a member of the administration council of the Intergroupe Francophone du Myélome (IFM) which he chaired from 2006 through 2009. He is also a member of the International Myeloma Working Group (IMWF) and President of the International Myeloma Society (IMS). Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents. He has served as the principal investigator of many international randomized phase 3 clinical trials and his research is widely published.
Professor Moreau has authored or coauthored more than 600 peer-reviewed articles that have appeared in high impact factor journals including the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, and Blood. He is a member of the editorial boards of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.”
Philippe Moreau, M.D., Ph.D.
Professor of Clinical Hematology at the University Hospital of Nantes at the Medical University of Nantes in France
Professor Moreau is a member of the administration council of the Intergroupe Francophone du Myélome (IFM) which he chaired from 2006 through 2009. He is also a member of the International Myeloma Working Group (IMWF) and President of the International Myeloma Society (IMS). Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents. He has served as the principal investigator of many international randomized phase 3 clinical trials and his research is widely published.
Professor Moreau has authored or coauthored more than 600 peer-reviewed articles that have appeared in high impact factor journals including the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, and Blood. He is a member of the editorial boards of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.”
Philippe Moreau, M.D., Ph.D.
Professor of Clinical Hematology at the University Hospital of Nantes at the Medical University of Nantes in France
Professor Moreau is a member of the administration council of the Intergroupe Francophone du Myélome (IFM) which he chaired from 2006 through 2009. He is also a member of the International Myeloma Working Group (IMWF) and President of the International Myeloma Society (IMS). Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents. He has served as the principal investigator of many international randomized phase 3 clinical trials and his research is widely published.
Professor Moreau has authored or coauthored more than 600 peer-reviewed articles that have appeared in high impact factor journals including the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, and Blood. He is a member of the editorial boards of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.”
Lawrence Olanoff, M.D., Ph.D.
Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Dr. Olanoff previously served as President and Chief Operating Officer for Forest Laboratories, Inc., and Chief Executive Officer of Celsion Corporation. During his career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals across several therapeutic areas. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University and has authored forty scientific publications on topics including drug delivery, pharmacokinetics and drug metabolism.
Lawrence Olanoff, M.D., Ph.D.
Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Dr. Olanoff previously served as President and Chief Operating Officer for Forest Laboratories, Inc., and Chief Executive Officer of Celsion Corporation. During his career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals across several therapeutic areas. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University and has authored forty scientific publications on topics including drug delivery, pharmacokinetics and drug metabolism.
Lawrence Olanoff, M.D., Ph.D.
Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Dr. Olanoff previously served as President and Chief Operating Officer for Forest Laboratories, Inc., and Chief Executive Officer of Celsion Corporation. During his career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals across several therapeutic areas. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University and has authored forty scientific publications on topics including drug delivery, pharmacokinetics and drug metabolism.